Alliances
One year after stepping down from her role as president and chief operating officer of Celgene, Jacqualyn (Jackie) Fouse has taken over the reins of Cambridge, Mass.-based Agios Pharmaceuticals.
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
MannKind Corporation, based in Westlake Village, California, and United Therapeutics, located in Silver Spring, Maryland, signed a worldwide exclusive license and collaboration deal to develop and commercialize a dry powder formulation of treprostinil.
Cystic fibrosis drugmaker Vertex Pharmaceuticals forged a three-year collaborative deal with U.K.-based machine learning specialist Genomics plc to improve the discovery of targets for precision medicines.
Heidelberg, Germany-based Affimed NV inked a licensing deal with Switzerland-based Roche for $96 million upfront, but that was only a fraction of the entire deal. Affimed shares rocketed, more than doubling to hit $148.07.
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
Changes are coming to the way 23andMe does business. The company will no longer provide “outside app developers” access to the company’s raw genetic data, CNBC reported this morning.
The NIH’s National Institutes on Aging (NIA) and the Alzheimer’s Association brought together various experts and stakeholders to create the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research.
Shares of Innovate Biopharmaceuticals are up more than 7 percent in premarket trading after the company announced it signed an agreement with privately-held Amarex Clinical Research to provide data management and biostatistics for its planned Phase III celiac disease trial.
Pfizer and Astellas Pharma announced they have amended the protocols for two Phase III clinical trials, ARCHES and EMBARK, to evaluate Xtandi (enzalutamide) in hormone-sensitive prostate cancer (HSPC). Both trials will wrap sooner than planned as a result.
PRESS RELEASES